Table 2.

Clinical features that differed in frequency between paraneoplastic and non-paraneoplastic patients

	Paraneoplastic, n = 9 (%)	Non-paraneoplastic, n = 35 (%)	P-valuea
Initial NMDAR-antibody level (mean and range)b	7855 (948–17 070)	2255 (0–16 208)	0.001
Confusion	9 (100)	20 (58)	0.02
Agitation	8 (89)	10 (29)	0.001
Amnesia	6 (67)	8 (24)	0.02
Spontaneous reduction in conscious level	8 (89)	12 (35)	0.008

Relapses were found in 10 of the non-paraneoplastic cases compared with none of the paraneoplastic cases, but this difference did not reach significance.

a Fisher’s exact test (two-tailed) was used for the comparisons (P-values have not been corrected for multiple comparisons).

b Measured using fluorescent immunoprecipitation assay with solubilised enhanced green fluorescent protein-tagged NR1 subunit.